-
Product Insights
Ependymoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ependymoma - Drugs In Development, 2023’, provides an overview of the Ependymoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Anaplastic Astrocytoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Anaplastic Astrocytoma - Drugs In Development, 2023’, provides an overview of the Anaplastic Astrocytoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Malignant Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Glioma - Drugs In Development, 2023’, provides an overview of the Malignant Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FOG-001 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FOG-001 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FOG-001 in Gastroesophageal (GE) Junction Carcinomas Drug Details: FOG-001...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAVO-412 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAVO-412 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAVO-412 in Non-Small Cell Lung Cancer Drug Details: TAVO-412...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIA-286156 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BIA-286156 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIA-286156 in Parkinson's Disease Drug Details: BIA-286156 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Eftozanermin Alfa in Solid Tumor Drug Details:Eftozanermin alfa (ABBV-621) is under development...